Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer

Yasuhide Kitagawa, Satoru Ueno, Kouji Izumi, Yoshifumi Kadono, Atsushi Mizokami, Shiro Hinotsu, Hideyuki Akaza, Mikio Namiki

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

Purpose: To investigate the clinical outcomes of metastatic prostate cancer patients and the relationship between nadir prostate-specific antigen (PSA) levels and different types of primary androgen deprivation therapy (PADT). This study utilized data from the Japan Study Group of Prostate Cancer registry, which is a large, multicenter, population-based database. Methods: A total of 2982 patients treated with PADT were enrolled. Kaplan–Meier analysis was used to compare progression-free survival (PFS) and overall survival (OS) in patients treated using combined androgen blockade (CAB) and non-CAB therapies. The relationships between nadir PSA levels and PADT type according to initial serum PSA levels were also investigated. Results: Among the 2982 enrolled patients, 2101 (70.5 %) were treated with CAB. Although CAB-treated patients had worse clinical characteristics, their probability of PFS and OS was higher compared with those treated with a non-CAB therapy. These results were due to a survival benefit with CAB in patients with an initial PSA level of 500–1000 ng/mL. Nadir PSA levels were significantly lower in CAB patients than in non-CAB patients with comparable initial serum PSA levels. Conclusions: A small survival benefit for CAB in metastatic prostate cancer was demonstrated in a Japanese large-scale prospective cohort study. The clinical significance of nadir PSA levels following PADT was evident, but the predictive impact of PSA nadir on OS was different between CAB and non-CAB therapy.

Original languageEnglish
Pages (from-to)319-327
Number of pages9
JournalWorld Journal of Urology
Volume34
Issue number3
DOIs
Publication statusPublished - Mar 1 2016

Keywords

  • Combined androgen blockade
  • Nadir PSA level
  • Outcome predictor
  • Primary androgen deprivation
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer'. Together they form a unique fingerprint.

Cite this